Fig. 6 | Nature Communications

Fig. 6

From: Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC

Fig. 6The alternative text for this image may have been generated using AI.

PHGDH contributed to Regorafenib and Lenvatinib resistances in HCC. a Treatment of Regorafenib at 10 μM and Lenvatinib at 40 μM for 48 h induced PHGDH, PSAT1, and PSPH expression in HCC cells. b Co-treatment of NCT-503 intensified Regorafenib and Lenvatinib-induced apoptosis in HCC cells, which can be rescued by addition of 5 mM NAC of 48 h treatment. c In total, 2514 compounds are ranked by their ability of inducing SSP in nine cell lines. The Sorafenib-like small molecules (n = 52) were significantly enriched in the highly ranked SSP-inducible compounds as suggested by GSEA pre-ranked enrichment analysis. d Most of the Sorafenib-like small molecules profoundly induced the mRNA expression of PHGDH, PSAT1, and PSPH in all cell lines. The error bar represents the SEM, n = 3 biological independent samples. Source data are provided as a Source Data file. (Student's t-test *P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page